BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2272 related articles for article (PubMed ID: 787436)

  • 21. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of immunochemotherapy in malignant melanoma].
    Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
    Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report.
    Mastrangelo MJ; Kim YH; Bornstein RS; Chee DO; Sulit HL; Yarbro JW; Prehn RT
    J Natl Cancer Inst; 1974 Jan; 52(1):19-24. PubMed ID: 4590009
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunology and the melanomas.
    Lewis MG
    Curr Top Microbiol Immunol; 1974; 63():49-84. PubMed ID: 4597749
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy of malignant melanoma.
    Terry WD
    N Engl J Med; 1980 Nov; 303(20):1174-5. PubMed ID: 6999351
    [No Abstract]   [Full Text] [Related]  

  • 26. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 27. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
    Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 29. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive transfer and specific active immunization of patients with malignant melanoma.
    Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
    Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
    [No Abstract]   [Full Text] [Related]  

  • 31. [Immunology of melanoma].
    Vanwijck R; Bernheim JL; Lejeune FJ
    Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
    [No Abstract]   [Full Text] [Related]  

  • 32. A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.
    Levy NL; Seigler HF; Shingleton WW
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1548-57. PubMed ID: 4421918
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 35. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease.
    Gross NJ; Eddie-Quartey AC
    Cancer; 1976 May; 37(5):2183-93. PubMed ID: 769946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant melanoma: specific immunity induced by bacillus Calmette-Guérin in BALB-c mice.
    Faraci RP; Schour L
    Science; 1974 Jul; 185(4145):68-9. PubMed ID: 4599426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological studies on malignant melanomas of man.
    Romsdahl MM; Cox IS
    Yale J Biol Med; 1973 Dec; 46(5):693-701. PubMed ID: 4205125
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of adjuvant immunotherapy to prevent central nervous system metastases in malignant melanoma patients.
    Grooms GA; Eilber FR; Morton DL
    J Surg Oncol; 1977; 9(2):147-53. PubMed ID: 325299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 114.